Mixed martial arts is the fastest-growing combat sport in the world. It is also, by the numbers, one of the most neurologically demanding. A 2022 analysis of 2,488 UFC bouts found that fighters absorb an average of 2.41 significant head strikes per minute — and that head trauma is the cause of ending 31.6% of all fights, accounting for 88.1% of all knockouts.[1] A separate systematic review found that head injuries constitute between 67.5% and 79.4% of all injuries by anatomic region in MMA competition.[2]
These are not abstract statistics. They describe a biological event — a cascade of neuroinflammation, excitotoxicity, and growth factor depletion — that begins within minutes of a significant head impact and, in the absence of adequate recovery, compounds with every subsequent bout. The long-term consequences are increasingly well-documented: longitudinal studies from the Cleveland Clinic's Professional Fighters Brain Health Study have shown measurable brain volume loss in the thalamus, corpus callosum, amygdala, and hippocampus in active fighters, with cognitive declines in verbal memory, processing speed, and executive function that track with years of exposure.[3]
What is less well-known is that a synthetic neuropeptide developed in Russia — Semax — appears to address several of the core biological mechanisms that drive this damage. This article examines what the peer-reviewed literature shows about both the neurological cost of repetitive head trauma in combat sports and the evidence for Semax as a neuroprotective and cognitive recovery agent.
The Neuroscience of a Knockout
A concussion is not simply a "brain bruise." It is a complex cascade of secondary injury processes that unfold over hours, days, and in some cases weeks after the initial impact. The primary injury — the mechanical force — triggers a depolarization wave across neurons, causing a massive release of glutamate, the brain's primary excitatory neurotransmitter. This glutamate surge overwhelms receptors, flooding neurons with calcium ions and triggering a metabolic crisis: cells demand more energy to restore ionic balance at the exact moment their mitochondria are least capable of providing it.[4]
Simultaneously, the brain's resident immune cells — microglia — activate in response to the injury signal. In the acute phase (within 24 hours), this activation is protective: microglia clear cellular debris and release repair signals. But after repetitive impacts, microglial activation becomes chronic and dysregulated. Studies in animal models of repetitive concussion have shown that this sustained activation leads to microglial engulfment of presynaptic excitatory synapses in the cortex and hippocampus — essentially, the brain's immune cells begin destroying the very connections responsible for learning and memory.[5]
The cytokine profile that follows a concussion is equally damaging. In the acute phase, pro-inflammatory cytokines including IL-1β, IL-6, TNF-α, and IFN-γ surge while anti-inflammatory signals like IL-4 and IL-13 are suppressed. In the chronic phase — which can persist for more than 30 days after a single significant impact — elevated IL-1β, IL-6, and TNF-α shift from reparative to maladaptive roles, perpetuating a self-reinforcing cycle of neuroinflammation and neuronal loss.[6]
BDNF: The Recovery Signal That Gets Suppressed
Brain-derived neurotrophic factor (BDNF) is perhaps the most important molecule in the post-injury recovery equation. BDNF supports neuronal survival, promotes synaptic plasticity, drives axonal repair, and is essential for the formation of new memories. After TBI, BDNF levels are acutely disrupted. A 2024 study measuring biomarkers in MMA fighters before and after sparring sessions found significant differences in BDNF levels between fighters and controls both at baseline and immediately post-sparring — with levels returning to baseline only at 72 hours.[7]
This transient suppression matters because BDNF is the signal the brain uses to rebuild. When it is repeatedly knocked down — as it is in fighters who spar multiple times per week — the cumulative deficit in neuroplasticity becomes measurable. The BDNF Val66Met polymorphism (rs6265), which reduces activity-dependent BDNF secretion, has been specifically linked to worse episodic memory and abnormal hippocampal activity after TBI, suggesting that BDNF pathway integrity is a critical determinant of recovery trajectory.[8]
What Semax Is
Semax is a synthetic heptapeptide with the sequence Met–Glu–His–Phe–Pro–Gly–Pro. It is an analog of the N-terminal fragment (4–10) of adrenocorticotropic hormone (ACTH), a naturally occurring peptide that plays a role in the stress response and has long been known to influence cognitive function. Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been approved in Russia for clinical use in stroke, brain hypoxia, and brain trauma since the 1990s.[9]
It is administered intranasally. Studies in rats have demonstrated that intranasal Semax penetrates the blood-brain barrier with significantly greater efficiency than intravenous delivery — approximately 0.093% of the total introduced radioactivity per gram reaches the brain within 2 minutes of intranasal administration, compared to roughly 0.01% via IV.[10] Despite a serum half-life of only a few minutes, its therapeutic effects persist for 20–24 hours after a single dose, driven in part by active metabolites including Pro-Gly-Pro that retain independent neurotrophic activity.[10]
The BDNF Connection
The most well-characterized mechanism of Semax is its upregulation of BDNF — the exact growth factor that repetitive head trauma suppresses. A landmark 2006 study published in Brain Research by Dolotov et al. found that a single intranasal application of Semax (50 μg/kg) in rats produced a 1.4-fold increase in BDNF protein levels in the hippocampus, a 1.6-fold increase in trkB tyrosine phosphorylation (the receptor activation signal), a 3-fold increase in exon III BDNF mRNA, and a 2-fold increase in trkB mRNA. These molecular changes were accompanied by a distinct improvement in conditioned avoidance reactions — a standard measure of learning and memory.[11]
A subsequent study confirmed that Semax also rapidly induces NGF (nerve growth factor) expression in the hippocampus and frontal cortex, with gene expression changes detectable within 20 minutes of a single intranasal dose and a second, sustained wave of upregulation at 90 minutes.[12] The pattern suggests that Semax does not simply spike BDNF once — it appears to activate a broader neurotrophin program that supports sustained repair signaling.
Neuroprotection After Brain Injury
The evidence for Semax in the context of acute brain injury is substantial. In a rat model of focal photoinduced ischemia of the prefrontal cortex, intranasal Semax administered for 6 days decreased the volume of cortical infarction and improved retention and performance of conditioned passive avoidance response — a direct measure of memory recovery.[13] A separate transcriptome analysis of rats with focal cerebral ischemia found that Semax significantly modulated the expression of immune response genes, enhancing antigen presentation signaling, influencing interferon pathways, and affecting cytokine and stress response genes — all in ways consistent with a shift toward neuroprotection and tissue repair.[14]
A 2021 proteomics study published in the International Journal of Molecular Sciences confirmed the neuroprotective effect of Semax at the protein expression level in a rat model of cerebral ischemia-reperfusion, finding changes in protein profiles consistent with reduced cell death, improved metabolic function, and enhanced repair signaling.[15]
Most recently, a 2026 preprint (under peer review) investigated intranasal Semax in a rat model of LPS-induced neuroinflammation — a model specifically designed to replicate the inflammatory cascade seen in brain injury and neurological disease. Rats receiving Semax (15 μg/kg/day, starting 6 hours post-LPS) showed significant improvement in motor activity, reduced anxiety-like behavior, and better performance in spatial memory and problem-solving tests compared to placebo, approaching control values by day 7.[16]
The Fighter Brain: What Recovery Actually Looks Like
The Cleveland Clinic's Professional Fighters Brain Health Study (PFBHS) is the most comprehensive longitudinal study of combat sports brain health in existence. A 2020 analysis of 204 participants found that active boxers showed average yearly volumetric declines in the left thalamus (102.3 mm³/year), mid anterior corpus callosum (10.2 mm³/year), and central corpus callosum (16.5 mm³/year) compared to controls. Retired fighters showed declines in the amygdala and hippocampus — the brain's memory and emotional regulation centers.[3]
A 2022 follow-up study offered a more hopeful finding: fighters who transitioned to inactive status showed improvements in verbal memory, psychomotor speed, and processing speed, alongside decreases in neurofilament light (NfL) — a biomarker of axonal damage — compared to active fighters who continued to decline.[17] This suggests the brain retains meaningful capacity for recovery when the source of repetitive trauma is removed. The question is how to accelerate and support that recovery window.
A 2025 two-year cohort study of competitive MMA fighters found progressive declines in mental processing speed, inhibitory control, and cognitive flexibility that were not seen in recreational practitioners — confirming that competition-level exposure, not training alone, drives the most significant neurological changes.[18]
Putting the Mechanisms Together
The biological case for Semax in the context of MMA and combat sports TBI rests on a direct alignment between what repetitive head trauma does to the brain and what Semax appears to do in response to it.
| Mechanism of TBI Damage | Semax's Documented Response | Key Study |
|---|---|---|
| BDNF suppression after head impact | 1.4-fold increase in hippocampal BDNF protein; 3-fold increase in BDNF mRNA | Dolotov et al., Brain Research, 2006 |
| trkB receptor downregulation | 1.6-fold increase in trkB tyrosine phosphorylation; 2-fold increase in trkB mRNA | Dolotov et al., Brain Research, 2006 |
| Neuroinflammatory cytokine cascade | Modulates immune response gene expression; shifts toward anti-inflammatory profile | Medvedeva et al., Mol Genet Genomics, 2017 |
| Cortical infarction and memory loss | Reduced infarction volume; improved memory retention in ischemia model | Romanova et al., Bull Exp Biol Med, 2006 |
| Neuroinflammation-driven cognitive impairment | Improved spatial memory and problem-solving; motor recovery to control values by day 7 | Belyakov & Tchang, SSRN preprint, 2026 |
| NGF depletion and reduced neurotrophin signaling | Rapid induction of NGF and BDNF gene expression in hippocampus and frontal cortex | Agapova et al., Mol Gen Mikrobiol Virusol, 2008 |
Safety and Clinical Use
Semax has been in clinical use in Russia since the 1990s for stroke, brain hypoxia, and brain trauma. Clinical trials have generally reported it to be well-tolerated, with a small percentage of adverse events.[10] Its synthetic structure — composed entirely of natural amino acids — means its biodegradation does not produce toxic byproducts. The absence of the Phe-Arg-Trp-Gly sequence present in natural ACTH(4–10) is thought to explain the absence of anxiogenic effects sometimes associated with melanocortin peptides.[10]
Human studies have demonstrated cognitive effects at doses as low as 16 μg/kg intranasally, with significant improvements in attention and short-term memory observed in healthy volunteers.[10] Chronic intranasal administration in animal models has shown anxiolytic and antidepressant effects attributed to activation of the serotonergic system — a finding relevant to the mood dysregulation and post-concussion depression that many fighters experience after significant head trauma.[10]
What This Means
The UFC and MMA community is increasingly aware of the long-term neurological stakes of the sport. Fighters retire earlier, commission-mandated medical suspensions have lengthened, and the conversation around brain health has moved from the margins to the center of the sport's self-examination. The biology of what happens inside a fighter's skull after a knockout — and after a career of sub-concussive accumulation — is now well-characterized enough to ask a more specific question: what interventions actually address those mechanisms?
Semax does not have a randomized controlled trial in MMA fighters. No peptide does. But the mechanistic alignment between what repetitive head trauma does and what Semax has been shown to do in peer-reviewed models of brain injury is precise enough to warrant serious attention. It upregulates the exact growth factor that head trauma suppresses. It modulates the neuroinflammatory cascade that drives chronic damage. It has been used clinically for brain injury in Russia for over three decades with a favorable safety record.
For athletes operating in a sport where the neurological cost of competition is real and cumulative, that alignment is worth understanding.